Tasman Therapeutics Announces Strategic Partnership with Osmind to Advance R-107 for Depressive Disorders

PartnershipR-107Positive

AI Analysis

Summary

Tasman Therapeutics and Osmind announced a strategic partnership to advance R-107, an investigational oral extended-release ketamine for depressive disorders, leveraging Osmind's real-world evidence platform and clinical network to support Tasman's Phase 3 ROCKET program and commercial launch.

Clinical Trial Data

Phase

Phase 3

Importance:6/10

Sentiment:

0.60

partnershipphase_3ketaminedepressionreal-world-evidenceat-home-administration

Related Companies

$NHPAP $RCKTW $WHEN

Read the original article

Published by PR Newswire Clinical Trials on August 12, 2026 12:00 PM

Read Original